Price$0.32-0.02 (-7.08%)
02:00 PM05:15 PM
News · 26 weeks18+500%
2025-10-262026-04-19
Mix990d
- SEC Filings5(56%)
- Other2(22%)
- Earnings2(22%)
Latest news
25 items- SECSEC Form D filed by Milestone Scientific Inc.D - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
- SECMilestone Scientific Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
- PRMilestone Scientific Inc. Completes $2.15 Million Private PlacementROSELAND, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the closing of a $2.15 million private placement of common stock and warrants, and an additional $2.69 million if cash warrants are fully exercised. "Today we strengthened our balance sheet and positioned the company to capitalize on the increasing demand we are seeing across our product platforms," said Eric Hines, Chief Executive Officer of Milestone Scientific. "This financing allows us to build on our progress, scaling investment in sales, inventory and digital marketing, wh
- SECMilestone Scientific Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
- PRMilestone Scientific Reports Financial Results for Fourth Quarter and Full Year 2025Q4 2025 Marks Transition from Restructuring to Growth For 2026, Expects Double-Digit Revenue Growth, 400% Increase in CompuFlo Sales, and Continued Progress Toward Profitability ROSELAND, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the year ended December 31, 2025. Eric Hines, Chief Executive Officer of Milestone Scientific commented: "When I joined Milestone in August 2025, we were in the middle of the third quarter following a period without consistent execut
- SECSEC Form 10-K filed by Milestone Scientific Inc.10-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
- PRMilestone Scientific Schedules Fourth Quarter and FY 2025 Financial Results and Business Update Conference CallROSELAND, N.J., March 26, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide objective, pressure-guided precision, today announced that it will host a conference call at 8:30 AM Eastern Time on Wednesday, April 1, 2026, to discuss the company's financial results for the fourth quarter and full year ended December 31, 2025, as well as the company's corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 875878. A webcast and replay of the
- PRMilestone Scientific Launches CompuFlo® Advisor Program to Accelerate Commercial Adoption and Drive Utilization Growth in Select MAC Jurisdictions; Plans National ExpansionROSELAND, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide objective, pressure-guided precision, today announced the launch of the CompuFlo® Advisor Program. This strategic initiative is designed to drive mainstream commercial adoption, increase recurring disposable revenue, and generate the clinical data necessary to optimize long-term Medicare reimbursement rates. The program, which commenced on February 1, 2026, targets high-volume interventional pain and anesthesia practices within key Medicare Administrative Contractor (MAC) jurisdictions, including Novitas, First Coast, Noridian,
- SECAmendment: Milestone Scientific Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K/A - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
- SECMilestone Scientific Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
- PRMilestone Scientific Launches The Wand® Ambassador Program to Expand Peer Engagement and Accelerate Market Adoption in DentistryROSELAND, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the launch of The Wand® Ambassador Program, a scalable peer-to-peer engagement initiative designed to expand clinical awareness, education, and adoption of The Wand® STA (Single Tooth Anesthesia®) System within the dental market. The program leverages experienced dental professionals to share real-world clinical insights, workflow considerations, and firsthand experiences with colleagues. This peer-driven approach is intended to increase high-quality engagement with prospective p
- SECMilestone Scientific Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
- SECMilestone Scientific Inc. filed SEC Form 8-K: Leadership Update8-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
- SECSEC Form 10-Q filed by Milestone Scientific Inc.10-Q - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
- PRMilestone Scientific Delivers Stable Revenue and Reduces Operating Expenses by Over $500 Thousand in the Third Quarter of 2025ROSELAND, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced financial results and provided a business update for the third quarter ended September 30, 2025, highlighting continued progress on the Company's transformation and growth initiatives. Eric Hines, Chief Executive Officer of Milestone Scientific, stated, "During the third quarter, we made measurable progress executing our plan to build a leaner, more focused organization capable of sustained growth and improved profitability. Through disciplined cost management and operati
- PRMilestone Scientific Schedules Third Quarter 2025 Financial Results and Business Update Conference CallROSELAND, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Friday, November 14th, 2025, to discuss the company's financial results for the third quarter ended September 30, 2025, as well as the company's corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 164353. A webcast and replay of the call may be acc
- SECSEC Form DEF 14A filed by Milestone Scientific Inc.DEF 14A - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
- INSIDERLarge owner Bp4 S.R.L. sold $84,884 worth of shares (194,427 units at $0.44), decreasing direct ownership by 2% to 8,896,765 units (SEC Form 4)4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)
- INSIDERLarge owner Bp4 S.R.L. sold $28,472 worth of shares (64,034 units at $0.44), decreasing direct ownership by 0.70% to 9,091,192 units (SEC Form 4)4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)
- INSIDERLarge owner Bp4 S.R.L. sold $27,273 worth of shares (50,158 units at $0.54), decreasing direct ownership by 0.44% to 9,155,226 units (SEC Form 4)4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)
- PRMilestone Scientific Highlights Operational Progress and Growth Initiatives Under New LeadershipROSELAND, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update highlighting the Company's transformation and growth initiatives under the leadership of its new Chief Executive Officer, Eric Hines. Since joining Milestone Scientific two months ago, Mr. Hines has conducted a comprehensive review of the Company's operations and implemented a series of strategic actions designed to accelerate growth, strengthen its competitive position, and improve operating efficiency. Actions within the dental segment include expanding the Com
- SECMilestone Scientific Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)
- PRMilestone Scientific Commits to Regaining NYSE American Compliance Following NotificationROSELAND, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has received a letter (the "Letter") from NYSE American LLC (the "NYSE American") dated October 8, 2025, stating that the Company is not in compliance with the continued listing standards set forth in Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide (the "Company Guide"). Section 1003(a)(ii) requires a listed company to have stockholders' equity of $4 million or more if it has reported losses from continuing operations and/or net losses in three of
- INSIDERLarge owner Bp4 S.R.L. sold $18,450 worth of shares (40,000 units at $0.46), decreasing direct ownership by 0.43% to 9,195,384 units (SEC Form 4)4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)
- INSIDERLarge owner Bp4 S.R.L. sold $8,636 worth of shares (19,210 units at $0.45), decreasing direct ownership by 0.21% to 9,235,384 units (SEC Form 4)4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)